AstraZeneca has signed a deal with Aurobindo Pharma which will see the Indian firm provide the Anglo-Swedish company with generics to be sold in emerging markets.

In a filing to the Bombay Stock Exchange, Aurobindo will supply several solid dosage and sterile products covering "a broad range of important therapeutic segments". These include anti-infectives, as well as cardiovascular and central nervous system drugs. Financial terms of the pact have not been disclosed.

Aurobindo chairman PV Ramprasad Reddy said the company's "proven track record in building strong, collaborative working relationships is a key driver for these strategic agreements with AstraZeneca". He added that the deal "will accelerate our growth plans and support our earnings".

Kaushik Banerjee, head of branded generics operations at AstraZeneca," said the agreements "will enable us to extend the range of branded medicines we are able to offer patients in emerging markets, where we see continued opportunities to grow our business". The deal comes a few months after AstraZeneca signed a deal with India’s Torrent Pharmaceuticals to get access to a portfolio of generics which it intends to brand and sell in emerging markets.

As for Aurobindo, it signed  a licensing deal with Pfizer last year to sell generics in emerging countries as well as in US and European markets.